The senior consultant for the department of neurology at the National Neuroscience Institute discussed his thoughts on improvements in the MS field in relation to this year's ECTRIMS conference. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
“In MS, I think we are really good at treating sort of inflammatory activity. In terms of reducing relapses and in terms of reducing the number of new MRI lesions, we have very good traffic with this.”
The 38th 2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress (ECTRIMS), taking place in Amsterdam, Netherlands, will host over 9000 participants, 200 speakers, and 50 international exhibitions. As one of the many, Tianrong Yeo, PhD, MBBS, MRCP, MMED, FAMS, MCI, will present a poster on neutralizing antibodies in patients with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and other neuroimmunological disorders, who’ve received SARS-CoV-2 mRNA vaccinations.
Yeo, a senior consultant in the department of neurology at the National Neuroscience Institute in Singapore, mentioned that he has a research interest in the environmental factors of MS and the treatment of inflammatory activity such as defining those on a molecular level along with the development of therapeutic interventions for them. He also spoke more about his clinical interest in neurologic conditions, for example, MS and NMOSD.
In a recent interview with NeurologyLive®, Yeo discussed the areas in MS from a clinical standpoint that need to be improved upon. In relation to the ECTRIMS conference, he also mentioned how he sees the space of MS moving in the next coming years.